{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:11:03Z","timestamp":1787065863364,"version":"build-2736575974"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:00:00Z","timestamp":1723075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:00:00Z","timestamp":1723075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100019446","name":"Medical and Health Science and Technology Development Project of Shandong Province","doi-asserted-by":"publisher","award":["202113010434"],"award-info":[{"award-number":["202113010434"]}],"id":[{"id":"10.13039\/501100019446","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Traditional Chinese Medicine Science and Technology Project of Shandong Province","award":["M-2023184"],"award-info":[{"award-number":["M-2023184"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-024-12742-4","type":"journal-article","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T13:02:21Z","timestamp":1723122141000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["5-Fluorouracil resistance due to sphingosine kinase 2 overexpression in colorectal cancer is associated with myeloid-derived suppressor cell-mediated immunosuppressive effects"],"prefix":"10.1186","volume":"24","author":[{"given":"Xiuyun","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yungao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5611-0952","authenticated-orcid":false,"given":"Wenna","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,8]]},"reference":[{"issue":"1","key":"12742_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"12742_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"12742_CR3","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2006.07.4187","volume":"25","author":"M Del Rio","year":"2007","unstructured":"Del Rio M, Molina F, Bascoul-Mollevi C, et al. Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan. J Clin Oncol. 2007;25(7):773\u201380.","journal-title":"J Clin Oncol"},{"issue":"9","key":"12742_CR4","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1002\/ijc.30232","volume":"139","author":"AR Pyzer","year":"2016","unstructured":"Pyzer AR, Cole L, Rosenblatt J, Avigan DE. Myeloid-derived suppressor cells as effectors of immune suppression in cancer. Int J Cancer. 2016;139(9):1915\u201326.","journal-title":"Int J Cancer"},{"key":"12742_CR5","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.3389\/fimmu.2019.01401","volume":"10","author":"P Ma","year":"2019","unstructured":"Ma P, Beatty PL, McKolanis J, Brand R, Schoen RE, Finn OJ. Circulating myeloid derived suppressor cells (MDSC) that accumulate in Premalignancy share phenotypic and functional characteristics with MDSC in Cancer. Front Immunol. 2019;10:1401.","journal-title":"Front Immunol"},{"issue":"8","key":"12742_CR6","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1182\/blood-2010-12-325753","volume":"118","author":"S Solito","year":"2011","unstructured":"Solito S, Falisi E, Diaz-Montero CM, et al. A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood. 2011;118(8):2254\u201365.","journal-title":"Blood"},{"issue":"8","key":"12742_CR7","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1158\/0008-5472.CAN-09-3690","volume":"70","author":"J Vincent","year":"2010","unstructured":"Vincent J, Mignot G, Chalmin F, et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell\u2013dependent antitumor immunity. Cancer Res. 2010;70(8):3052\u201361.","journal-title":"Cancer Res"},{"issue":"9","key":"12742_CR8","doi-asserted-by":"publisher","first-page":"5398","DOI":"10.4049\/jimmunol.166.9.5398","volume":"166","author":"DI Gabrilovich","year":"2001","unstructured":"Gabrilovich DI, Velders MP, Sotomayor EM, Kast WM. Mechanism of immune dysfunction in cancer mediated by immature Gr-1\u2009+\u2009myeloid cells. J Immunol. 2001;166(9):5398\u2013406.","journal-title":"J Immunol"},{"issue":"1","key":"12742_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00262-014-1639-3","volume":"64","author":"MN Messmer","year":"2015","unstructured":"Messmer MN, Netherby CS, Banik D, Abrams SI. Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy. Cancer Immunol Immunother. 2015;64(1):1\u201313.","journal-title":"Cancer Immunol Immunother"},{"issue":"20","key":"12742_CR10","doi-asserted-by":"publisher","first-page":"10019","DOI":"10.1158\/0008-5472.CAN-07-2354","volume":"67","author":"SK Bunt","year":"2007","unstructured":"Bunt SK, Yang L, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res. 2007;67(20):10019\u201326.","journal-title":"Cancer Res"},{"issue":"2","key":"12742_CR11","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1158\/0008-5472.CAN-17-3026","volume":"79","author":"MF Al Sayed","year":"2019","unstructured":"Al Sayed MF, Amrein MA, B\u00fchrer ED, et al. T-cell-secreted TNF\u03b1 induces emergency myelopoiesis and myeloid-derived suppressor cell differentiation in Cancer. Cancer Res. 2019;79(2):346\u201359.","journal-title":"Cancer Res"},{"issue":"1","key":"12742_CR12","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s13277-013-1051-1","volume":"35","author":"Q Wang","year":"2014","unstructured":"Wang Q, Li J, Li G, et al. Prognostic significance of sphingosine kinase 2 expression in non-small cell lung cancer. Tumour Biol. 2014;35(1):363\u20138.","journal-title":"Tumour Biol"},{"issue":"16","key":"12742_CR13","doi-asserted-by":"publisher","first-page":"10422","DOI":"10.1074\/jbc.M900735200","volume":"284","author":"S Nemoto","year":"2009","unstructured":"Nemoto S, Nakamura M, Osawa Y, et al. Sphingosine kinase isoforms regulate oxaliplatin sensitivity of human colon cancer cells through ceramide accumulation and akt activation. J Biol Chem. 2009;284(16):10422\u201332.","journal-title":"J Biol Chem"},{"issue":"8","key":"12742_CR14","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/j.biopha.2014.10.001","volume":"68","author":"JH Chu","year":"2014","unstructured":"Chu JH, Gao ZH, Qu XJ. Down-regulation of sphingosine kinase 2 (SphK2) increases the effects of all-trans-retinoic acid (ATRA) on colon cancer cells. Biomed Pharmacother. 2014;68(8):1089\u201397.","journal-title":"Biomed Pharmacother"},{"issue":"24","key":"12742_CR15","doi-asserted-by":"publisher","first-page":"39605","DOI":"10.18632\/oncotarget.17174","volume":"8","author":"WN Shi","year":"2017","unstructured":"Shi WN, Cui SX, Song ZY, et al. Overexpression of SphK2 contributes to ATRA resistance in colon cancer through rapid degradation of cytoplasmic RXR\u03b1 by K48\/K63-linked polyubiquitination. Oncotarget. 2017;8(24):39605\u201317.","journal-title":"Oncotarget"},{"issue":"9","key":"12742_CR16","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1002\/ijc.24594","volume":"125","author":"A Weigert","year":"2009","unstructured":"Weigert A, Schiffmann S, Sekar D, et al. Sphingosine kinase 2 deficient tumor xenografts show impaired growth and fail to polarize macrophages towards an anti-inflammatory phenotype. Int J Cancer. 2009;125(9):2114\u201321.","journal-title":"Int J Cancer"},{"issue":"29","key":"12742_CR17","doi-asserted-by":"publisher","first-page":"5214","DOI":"10.1038\/s41388-020-1352-y","volume":"39","author":"YH Zhang","year":"2020","unstructured":"Zhang YH, Shi WN, Wu SH, et al. SphK2 confers 5-fluorouracil resistance to colorectal cancer via upregulating H3K56ac-mediated DPD expression. Oncogene. 2020;39(29):5214\u201327.","journal-title":"Oncogene"},{"issue":"1","key":"12742_CR18","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13046-015-0205-y","volume":"34","author":"C Xun","year":"2015","unstructured":"Xun C, Chen MB, Qi L, et al. Targeting sphingosine kinase 2 (SphK2) by ABC294640 inhibits colorectal cancer cell growth in vitro and in vivo. J Exp Clin Cancer Res. 2015;34(1):94.","journal-title":"J Exp Clin Cancer Res"},{"key":"12742_CR19","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/bs.apcsb.2019.11.003","volume":"120","author":"OA Sukocheva","year":"2020","unstructured":"Sukocheva OA, Lukina E, McGowan E, Bishayee A. Sphingolipids as mediators of inflammation and novel therapeutic target in inflammatory bowel disease. Adv Protein Chem Struct Biol. 2020;120:123\u201358.","journal-title":"Adv Protein Chem Struct Biol"},{"issue":"8","key":"12742_CR20","doi-asserted-by":"publisher","first-page":"6337","DOI":"10.1002\/jcb.26707","volume":"119","author":"P Fu","year":"2018","unstructured":"Fu P, Ebenezer DL, Ha AW, Suryadevara V, Harijith A, Natarajan V. Nuclear lipid mediators: role of nuclear sphingolipids and sphingosine-1-phosphate signaling in epigenetic regulation of inflammation and gene expression. J Cell Biochem. 2018;119(8):6337\u201353.","journal-title":"J Cell Biochem"},{"issue":"21","key":"12742_CR21","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1158\/0008-5472.CAN-17-0307","volume":"77","author":"T Li","year":"2017","unstructured":"Li T, Fan J, Wang B, et al. TIMER: a web server for Comprehensive Analysis of Tumor-infiltrating Immune cells. Cancer Res. 2017;77(21):e108\u201310.","journal-title":"Cancer Res"},{"key":"12742_CR22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jbo.2018.01.002","volume":"11","author":"Y Wang","year":"2018","unstructured":"Wang Y, Zhang X, Yang L, Xue J, Hu G. Blockade of CCL2 enhances immunotherapeutic effect of anti-PD1 in lung cancer. J Bone Oncol. 2018;11:27\u201332.","journal-title":"J Bone Oncol"},{"issue":"1","key":"12742_CR23","doi-asserted-by":"publisher","first-page":"5321","DOI":"10.1038\/s41467-020-19173-2","volume":"11","author":"YH Cho","year":"2020","unstructured":"Cho YH, Ro EJ, Yoon JS, et al. 5-FU promotes stemness of colorectal cancer via p53-mediated WNT\/\u03b2-catenin pathway activation. Nat Commun. 2020;11(1):5321.","journal-title":"Nat Commun"},{"issue":"11","key":"12742_CR24","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1093\/jnci\/djr153","volume":"103","author":"FA Sinicrope","year":"2011","unstructured":"Sinicrope FA, Foster NR, Thibodeau SN, et al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst. 2011;103(11):863\u201375.","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"12742_CR25","doi-asserted-by":"publisher","first-page":"8455","DOI":"10.1007\/s13277-015-4700-8","volume":"37","author":"L Zhang","year":"2016","unstructured":"Zhang L, Liu X, Zuo Z, Hao C, Ma Y. Sphingosine kinase 2 promotes colorectal cancer cell proliferation and invasion by enhancing MYC expression. Tumour Biol. 2016;37(6):8455\u201360.","journal-title":"Tumour Biol"},{"issue":"19","key":"12742_CR26","doi-asserted-by":"publisher","first-page":"10767","DOI":"10.3390\/ijms221910767","volume":"22","author":"P Grb\u010di\u0107","year":"2021","unstructured":"Grb\u010di\u0107 P, Eichmann TO, Kraljevi\u0107 Paveli\u0107 S, Sedi\u0107 M. The Sphingosine kinase 2 inhibitor ABC294640 restores the sensitivity of BRAFV600E mutant Colon cancer cells to Vemurafenib by reducing AKT-Mediated expression of Nucleophosmin and translationally-controlled tumour protein. Int J Mol Sci. 2021;22(19):10767.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"12742_CR27","first-page":"433","volume":"33","author":"DD Song","year":"2018","unstructured":"Song DD, Zhou JH, Sheng R. Regulation and function of sphingosine kinase 2 in diseases. Histol Histopathol. 2018;33(5):433\u201345.","journal-title":"Histol Histopathol"},{"key":"12742_CR28","doi-asserted-by":"publisher","first-page":"148063","DOI":"10.1016\/j.gene.2023.148063","volume":"897","author":"G da Silva","year":"2024","unstructured":"da Silva G, Milan TM, Leopoldino AM. The accumulation of sphingosine kinase 2 disrupts the DNA damage response and promotes resistance to genotoxic agents. Gene. 2024;897:148063.","journal-title":"Gene"},{"issue":"6","key":"12742_CR29","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1136\/thoraxjnl-2018-212378","volume":"74","author":"DL Ebenezer","year":"2019","unstructured":"Ebenezer DL, Berdyshev EV, Bronova IA, et al. Pseudomonas aeruginosa stimulates nuclear sphingosine-1-phosphate generation and epigenetic regulation of lung inflammatory injury. Thorax. 2019;74(6):579\u201391.","journal-title":"Thorax"},{"key":"12742_CR30","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/1476-4598-13-179","volume":"13","author":"M Li","year":"2014","unstructured":"Li M, Shi H, Mu Y, et al. Effective inhibition of melanoma tumorigenesis and growth via a new complex vaccine based on NY-ESO-1-alum-polysaccharide-HH2. Mol Cancer. 2014;13:179.","journal-title":"Mol Cancer"},{"issue":"12","key":"12742_CR31","doi-asserted-by":"publisher","first-page":"6523","DOI":"10.1172\/JCI125297","volume":"130","author":"CJ Studstill","year":"2020","unstructured":"Studstill CJ, Pritzl CJ, Seo YJ, et al. Sphingosine kinase 2 restricts T cell immunopathology but permits viral persistence. J Clin Invest. 2020;130(12):6523\u201338.","journal-title":"J Clin Invest"},{"issue":"7","key":"12742_CR32","doi-asserted-by":"publisher","first-page":"e106065","DOI":"10.15252\/embj.2020106065","volume":"40","author":"J Tian","year":"2021","unstructured":"Tian J, Zhang D, Kurbatov V, et al. 5-Fluorouracil efficacy requires anti-tumor immunity triggered by cancer-cell-intrinsic STING. Embo j. 2021;40(7):e106065.","journal-title":"Embo j"},{"issue":"5795","key":"12742_CR33","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1126\/science.1129139","volume":"313","author":"J Galon","year":"2006","unstructured":"Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960\u20134.","journal-title":"Science"},{"key":"12742_CR34","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.3389\/fimmu.2019.01181","volume":"10","author":"T Rivera Vargas","year":"2019","unstructured":"Rivera Vargas T, Apetoh L. Can immunogenic chemotherapies relieve Cancer Cell Resistance to Immune Checkpoint inhibitors? Front Immunol. 2019;10:1181.","journal-title":"Front Immunol"},{"issue":"13","key":"12742_CR35","doi-asserted-by":"publisher","first-page":"5303","DOI":"10.1007\/s00018-021-03828-4","volume":"78","author":"ILAA Mart\u00ed","year":"2021","unstructured":"Mart\u00ed ILAA, Reith W. Arginine-dependent immune responses. Cell Mol Life Sci. 2021;78(13):5303\u201324.","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"12742_CR36","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s12943-022-01657-y","volume":"21","author":"Y Wu","year":"2022","unstructured":"Wu Y, Yi M, Niu M, Mei Q, Wu K. Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy. Mol Cancer. 2022;21(1):184.","journal-title":"Mol Cancer"},{"issue":"8","key":"12742_CR37","doi-asserted-by":"publisher","first-page":"4233","DOI":"10.1182\/blood-2007-07-099226","volume":"111","author":"K Movahedi","year":"2008","unstructured":"Movahedi K, Guilliams M, Van den Bossche J, et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood. 2008;111(8):4233\u201344.","journal-title":"Blood"},{"issue":"6","key":"12742_CR38","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1189\/jlb.4RI0515-204R","volume":"98","author":"T Condamine","year":"2015","unstructured":"Condamine T, Mastio J, Gabrilovich DI. Transcriptional regulation of myeloid-derived suppressor cells. J Leukoc Biol. 2015;98(6):913\u201322.","journal-title":"J Leukoc Biol"},{"issue":"1","key":"12742_CR39","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.it.2010.10.002","volume":"32","author":"T Condamine","year":"2011","unstructured":"Condamine T, Gabrilovich DI. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol. 2011;32(1):19\u201325.","journal-title":"Trends Immunol"},{"issue":"1","key":"12742_CR40","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ccell.2014.11.009","volume":"27","author":"MR Rutkowski","year":"2015","unstructured":"Rutkowski MR, Stephen TL, Svoronos N, et al. Microbially driven TLR5-dependent signaling governs distal malignant progression through tumor-promoting inflammation. Cancer Cell. 2015;27(1):27\u201340.","journal-title":"Cancer Cell"},{"issue":"4","key":"12742_CR41","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1172\/JCI60083","volume":"123","author":"D Vasquez-Dunddel","year":"2013","unstructured":"Vasquez-Dunddel D, Pan F, Zeng Q, et al. STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. J Clin Invest. 2013;123(4):1580\u20139.","journal-title":"J Clin Invest"},{"issue":"8","key":"12742_CR42","doi-asserted-by":"publisher","first-page":"4499","DOI":"10.4049\/jimmunol.0802740","volume":"182","author":"S Ostrand-Rosenberg","year":"2009","unstructured":"Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol. 2009;182(8):4499\u2013506.","journal-title":"J Immunol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12742-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-12742-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12742-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T14:11:22Z","timestamp":1723126282000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-12742-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,8]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["12742"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-12742-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,8]]},"assertion":[{"value":"25 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"983"}}